Advertisement


Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

COVID-19 and Cancer Care

Advertisement

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.



Related Videos

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 5

For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 1

Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma?

Recorded April 21, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 6

Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?

Recorded April 21, 2020.

Global Cancer Care
COVID-19

Giorgio V. Scagliotti, MD, PhD, on the Oncoming Waves of COVID-19: Italy’s Experience

Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the progression of COVID-19 through his community and how, in nursing homes, lack of experience dealing with a pandemic is fueling a third wave of the virus in Italy. Filmed April 15, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 2

During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission?

Recorded April 21, 2020.

Advertisement

Advertisement




Advertisement